Biokine Therapeutics Ltd.
http://biokine.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biokine Therapeutics Ltd.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
Chinese Language Podcast: Biokin/BMS Deal, Developments At Pfizer, BlissBio, WuXi Biologics
Chengdu-based Biokin has just signed a $8.4bn licensing deal with BMS for an ADC asset, while Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in China. Meanwhile, BlissBio has released new clinical data for its HER2-targeting ADC and shares in WuXi Biologics have plummeted following its latest business updates.
BioLineRx's CXCR4 Antagonist: Promising For Stem Cell Mobilization And AML
Numerous companies are evaluating CXCR4 antagonists in early-stage clinical studies for their potential in stem cell transplantation, acute myeloid leukemia and other disorders, and BioLineRx's lead compound appears to be a frontrunner in the race to market.
Deals Shaping The Medical Industry, October 2012
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Clal Biotechnology Industries Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice